GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of ACHIEVE: what the trials say vs what this community says — 49 comments in the full submission. View in context.
933
c/orforglipron·submitted 3 months ago by u/honest_syringe_maybe

ACHIEVE: what the trials say vs what this community says

Questionbranch of 7 comments

ACHIEVE: what the trials say vs what this community says. Change my mind, genuinely — I have no stake in being right about this. Daily rather than weekly sounds trivial until you think about what a missed dose means in each case. The no-timing-restriction thing is the part I would care about most in practice, and it…

Read the full submission and all 49 comments →

This branch

7 comments, started 3 months ago
u/maren_sorensen46 points·3 months ago

ATTAIN and ACHIEVE are the programmes to keep straight

replysharereportpermalink
u/bruno_dumitru13 points·3 months ago

Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.

replysharereportpermalink
u/bastian_ekstrom4 points·3 months ago

the boards keep comparing it to injectables at matched doses, which is meaningless

replysharereportpermalink
u/fasting_insulin_f5 points·3 months ago

This. The absence of food and water timing restrictions is the practical difference people will actually notice.

replysharereportpermalink
u/lukas_delgado1 point·3 months ago

phase 3 is where the comparison becomes fair

replysharereportpermalink
u/clara_weiss9 points·3 months ago·edited

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

replysharereportpermalink
u/ines_lindqvist37 points·3 months ago

small molecule, not a peptide, and that changes everything about it

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →